MaxCyte shares gain 5% on raised full-year revenue guidance
Commercial cell-engineering company MaxCyte (MXCT:AIM) increased full-year revenue guidance on Tuesday after reporting a strong first quarter to 31 March 2022.Based on expectations for the core business which generates revenue from...
10 May 2022
